Epalrestat is an aldose reductase inhibitor, mainly used in the treatment of diabetic neuropathy. Oral administration of Epalrestat to patients with glaucoma does not usually have a significant effect on intraocular pressure, but the medication should be used under the guidance of a doctor. 1. Dosage form and indications: Epalrestat is commonly available in tablets and capsules, which are western drugs. Epalrestat can inhibit diabetic peripheral neuropathy, which can improve patients’ neurological dysfunction and self-perceived symptoms. Oral administration to patients with glaucoma usually does not affect intraocular pressure, and there is no relevant evidence-based evidence that this product affects intraocular pressure. 2. Adverse reactions: occasional erythema, pruritus, diarrhea, nausea, vomiting, abdominal pain. 3. Contraindications: allergic to any component of the product is prohibited; contraindicated in pregnancy and lactation. 4. Precautions: caution for allergic individuals; once allergic manifestations occur, the drug should be immediately discontinued and appropriate treatment. Epalrestat should be taken under the guidance of a physician, do not self-medication.